Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Recombinant Hepatitis B Vaccine (Hansenula Polymorpha) in Adults, Children, and Neonates
NCT04075201Phase 1Completed
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Jul 2019
- Primary completion
- May 2021
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Hepatitis B vaccine in hepatitis B (HBV) (5 arms), sponsored by Sinovac Biotech Ltd. Primary endpoint: Incidence of adverse reactions at 30 days. Started Jul 2019; status: completed.
02
Drugs
Hepatitis B vaccine
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT04075201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04075201.